SG Americas Securities LLC Purchases New Stake in ADMA Biologics Inc $ADMA

SG Americas Securities LLC purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,252 shares of the biotechnology company’s stock, valued at approximately $1,099,000.

Several other institutional investors have also recently added to or reduced their stakes in ADMA. Royal Bank of Canada raised its holdings in ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in ADMA Biologics in the first quarter valued at $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after acquiring an additional 305,064 shares in the last quarter. Norges Bank acquired a new stake in ADMA Biologics in the second quarter valued at $549,000. Finally, EverSource Wealth Advisors LLC raised its holdings in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 6.2%

Shares of NASDAQ:ADMA opened at $9.83 on Thursday. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of 16.38 and a beta of 0.82. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $25.67. The company’s fifty day moving average is $14.36 and its two-hundred day moving average is $16.05. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The company had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.46 earnings per share. Equities analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ADMA. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.